Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study

V. Renard, L. Staelens, A. Signore, S. Van Belle, R. A. Dierckx, C. Van De Wiele*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    9 Citations (Scopus)


    Aim This pilot study reports on the uptake of I-123-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment.

    Methods. Nine consecutive patients with MRCC underwent an I-123-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al.

    Results. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and I patient a summed score of 3. Uptake of I-123-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in I patient with a summed score of 3 and in 1 with a summed score of 2.

    Conclusion In this small series of patients with MRCC, I-123-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of I-123-IL2 in MRCC and the response to IL-2 therapy.

    Original languageEnglish
    Pages (from-to)352-356
    Number of pages5
    JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
    Issue number4
    Publication statusPublished - Dec-2007
    Event18th International Congress of the International-Research-Group-in-Immuno-Scintigraphy-and-Therapy (IRIST) -
    Duration: 1-Jul-2006 → …


    • carcinoma
    • renal cell
    • interleukins
    • scintigraphy
    • radiolabelling

    Cite this